^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2 stimulant

    Related drugs:
    6d
    Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=182, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Yutuo (zimberelimab) • GS-4528
    11d
    Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer (clinicaltrials.gov)
    P1, N=3, Terminated, National Cancer Institute (NCI) | Phase classification: P1/2 --> P1
    Phase classification
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Proleukin (aldesleukin)
    11d
    IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University
    New P1/2 trial
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel
    12d
    KEYNOTE-A78: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=80, Completed, Cue Biopharma | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • CUE-101
    18d
    Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
    CA-induced immune pharmacodynamic effects in peripheral blood and in the tumor microenvironment without preferential Treg cell activation in patients with metastatic/unresectable CEA+ solid tumors.
    P1 data • Journal • PD(L)-1 Biomarker • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • CD14 (CD14 Molecule)
    |
    cergutuzumab amunaleukin (RG7813)
    19d
    Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=48, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    19d
    Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (clinicaltrials.gov)
    P1/2, N=30, Suspended, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Dec 2026 | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    LDH elevation
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Lymphir (denileukin diftitox-cxdl)
    19d
    Theratri: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors (clinicaltrials.gov)
    P1, N=56, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FAP (Fibroblast activation protein, alpha)
    |
    darleukin (L19IL2)
    26d
    ACT: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, AgonOx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
    |
    AGX-148
    26d
    Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    capecitabine • oxaliplatin
    1m
    STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, City of Hope Medical Center | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    1m
    KEYNOTE-E46: Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • igrelimogene litadenorepvec (TILT-123)